Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study - PubMed
4 hours ago
- #multi-omics
- #liquid biopsy
- #multi-cancer detection
- The PROMISE study explores multi-omics liquid biopsy approaches for early detection of multiple cancers.
- The study investigates the integration of cfDNA methylation, proteins, and mutations to improve multi-cancer detection blood tests (MCDBTs).
- Blood samples from 1,706 participants (840 non-cancer, 866 cancer) were analyzed, divided into training and validation sets.
- Methylation-based classifiers outperformed mutation-based and protein-based classifiers in cancer detection.
- Protein markers provided complementary value to methylation-based classifiers, improving detection sensitivity to 75.1% at 98.8% specificity.
- The multimodal classifier combining methylation and protein features showed high accuracy in identifying liver and ovarian cancers.
- The study suggests protein markers enhance methylation-based classifiers, particularly for liver and ovarian cancers.